Last reviewed · How we verify
Abatacept SC
Abatacept is a fusion protein that inhibits T cell activation by blocking the CD80/CD86 costimulatory signal required for full T cell engagement.
Abatacept is a fusion protein that inhibits T cell activation by blocking the CD80/CD86 costimulatory signal required for full T cell engagement. Used for Rheumatoid arthritis, Polyarticular juvenile idiopathic arthritis, Psoriatic arthritis.
At a glance
| Generic name | Abatacept SC |
|---|---|
| Also known as | Subcutaneous Abatacept, Orencia |
| Sponsor | University Medical Center Groningen |
| Drug class | Costimulation modulator; T cell inhibitor |
| Target | CD80, CD86 |
| Modality | Small molecule |
| Therapeutic area | Immunology |
| Phase | Phase 3 |
Mechanism of action
Abatacept (CTLA4-Ig) binds to CD80 and CD86 molecules on antigen-presenting cells, preventing their interaction with CD28 on T cells. This blocks the second signal needed for T cell activation, thereby suppressing the adaptive immune response. The subcutaneous formulation allows for patient self-administration while maintaining the same mechanism of action as the intravenous form.
Approved indications
- Rheumatoid arthritis
- Polyarticular juvenile idiopathic arthritis
- Psoriatic arthritis
- Ankylosing spondylitis
Common side effects
- Infection (upper respiratory, urinary tract)
- Headache
- Nausea
- Dizziness
- Injection site reactions
Key clinical trials
- Study of COYA 302 for the Treatment of ALS (PHASE2)
- Rituximab-pvvr and Abatacept vs Rituximab-pvvr Alone in New Onset Type 1 Diabetes (PHASE2)
- Abatacept, Ixazomib Citrate, and Dexamethasone in Treating Patients With Multiple Myeloma Resistant to Chemotherapy (PHASE2)
- A Study to Compare the Response to Treatment With Abatacept vs Adalimumab, on Background Methotrexate, in Adults With Early, Seropositive, and Shared Epitope-positive Rheumatoid Arthritis and an Inadequate Response to Methotrexate (PHASE3)
- Treg Modulation With CD28 and IL-6 Receptor Antagonists (PHASE1, PHASE2)
- Early Markers of Disease and Response to Therapy (EARLY_PHASE1)
- Trial to Evaluate the Efficacy and Safety of Abatacept in Combination With Standard Therapy Compared to Standard Therapy Alone in Improving Disease Activity in Adults With Active Idiopathic Inflammatory Myopathy (PHASE3)
- Pharmacokinetics, Efficacy and Safety of Abatacept Administered Subcutaneously (SC) in Children and Adolescents With Active Polyarticular Juvenile Idiopathic Arthritis (pJIA) and Inadequate Response (IR) to Biologic or Non Biologic Disease Modifying Anti-rheumatic Drugs (DMARDs) (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Abatacept SC CI brief — competitive landscape report
- Abatacept SC updates RSS · CI watch RSS
- University Medical Center Groningen portfolio CI